Clinical Impact of Revised Cefepime Breakpoint in Patients with Enterobacteriaceae Bacteremia

Kap Sum Foong, Abigail L. Carlson, Satish Munigala, Carey Ann D. Burnham, David K. Warren

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

The impact of the revised Clinical and Laboratory Standards Institute interpretative criteria for cefepime in Enterobacteriaceae remains unclear. We applied the new breakpoint on 644 previously defined cefepime-susceptible Enterobacteriaceae isolates. We found no differences in mortality or microbiological failure, regardless of isolates being susceptible or cefepime-susceptible dose-dependent by current criteria.

Original languageEnglish
Article numberofz341
JournalOpen Forum Infectious Diseases
Volume6
Issue number8
DOIs
StatePublished - Aug 1 2019

Keywords

  • bacteremia
  • cefepime
  • cefepime-susceptible dose-dependent
  • CLSI
  • Enterobacteriaceae
  • susceptibility

Fingerprint Dive into the research topics of 'Clinical Impact of Revised Cefepime Breakpoint in Patients with Enterobacteriaceae Bacteremia'. Together they form a unique fingerprint.

Cite this